天坛生物 (600161)

Beijing Tiantan Biological Products Corporation Limited

ASH

Tags

300ESG Index300 Non-Cyclical IndexMSCI Mid Cap IndexSSE 380 IndexSSE Corporate Governance IndexSSE Mixed-Ownership Reform IndexCSI 200 IndexCSI Central State-Owned Enterprises IndexPharmaceutical ManufacturingPharmaceuticals and HealthcareState-Owned Enterprise ReformGene ConceptCentral State-Owned Enterprises 100 IndexEmerging Markets IndexCSI 300 IndexBiological ProductsHepatitis ConceptMargin Trading and Securities LendingNon-Cyclical Stocks

K-Line Chart

No K-line data

Stock Details

1. Key Indicators

  • Total Shares(W): 197737.14
  • Circulating A-Shares(W): 197737.14
  • Earnings Per Share(RMB): 0.4100
  • Net Assets Per Share(RMB): 5.7971
  • Operating Revenue(W RMB): 446507.19
  • Total Profit(W RMB): 134739.73
  • **Net Profit Attributable to Parent(W RMB) **: 81868.63
  • Net Profit Growth Rate(%): -22.16
  • Weighted Return on Equity(%): 7.1600
  • Operating Cash Flow Per Share(RMB): 0.0590
  • Undistributed Profit Per Share(RMB): 3.3776
  • Capital Reserve Per Share(RMB): 1.2456

2. Main Business

The main business covers:

  • Research, development, and production of blood products using healthy human plasma and specifically immunized human plasma as raw materials, as well as employing gene recombination technology.
  • Operation of blood product business.

3. Company Basic Information

  • Company Name: Beijing Tiantan Biological Products Co., Ltd.
  • Listing Date: 1998-06-16
  • Industry: Pharmaceutical Manufacturing
  • Address: Room 521, Building 8, No. 6 Courtyard, Boxing Second Road, Beijing Economic-Technological Development Area, Beijing
  • Website: https://www.tiantanbio.com/
  • Company Profile: The company was exclusively established by the Beijing Biological Products Institute in June 1998. The promoter contributed its net assets, converted into 90 million state-owned legal person shares. After the public offering on May 18, 1998, the total share capital at the time of listing reached 120 million shares. The 3 million internal employee shares and the 27 million public shares were listed for trading on the Shanghai Stock Exchange on June 16, 1998, and the internal employee shares became tradable after six months.

4. Top 10 Circulating Shareholders

Rank Institution Name Institution Type Shares Held (W) Percentage Held (%)
1 China National Biotec Group Co., Ltd. General Legal Person 90250.05 45.64
2 Chengdu Institute of Biological Products Co., Ltd. General Legal Person 6981.74 3.53
3 Hong Kong Securities Clearing Company Ltd. Northbound Funds 5433.12 2.75
4 Huatai-Pinebridge CSI 300 ETF Fund 2027.00 1.03
5 Beijing Institute of Biological Products Co., Ltd. General Legal Person 1880.24 0.95
6 E Fund CSI 300 Healthcare ETF Fund 1486.85 0.75
7 E Fund CSI 300 Index Fund Fund 1460.14 0.74
8 Emi Kaixin Value Select Hybrid Securities Investment Fund Class A Fund 22.00 0.01
9 Qianhai Kaiyuan Shanghai-Hong Kong-Shenzhen Innovation Growth Flexible Allocation Hybrid Securities Investment Fund Class A Fund 16.34 0.01
10 Emi Xinxuan Quality Hybrid Securities Investment Fund Class A Fund 16.00 0.01

5. Concept Sectors

  • Gene Concept
  • Hepatitis Concept

Remarks

  • Data update date: 2025-09-30
  • Data source: Public Market Information